GlaxoSmithKline plc Receives Consensus Recommendation of “Hold” from Analysts (NYSE:GSK)
Shares of GlaxoSmithKline plc (NYSE:GSK) have received an average rating of “Hold” from the twenty analysts that are covering the stock, Analyst RN reports. Three research analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $52.67.
Several analysts have recently commented on the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday. Separately, analysts at Argus cut their price target on shares of GlaxoSmithKline plc from $65.00 to $55.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. Finally, analysts at Galvan Research reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th.
GlaxoSmithKline plc (NYSE:GSK) opened at 47.68 on Monday. GlaxoSmithKline plc has a one year low of $46.01 and a one year high of $56.73. The stock’s 50-day moving average is $49.78 and its 200-day moving average is $53.20. The company has a market cap of $114.5 billion and a price-to-earnings ratio of 14.84.
GlaxoSmithKline plc (NYSE:GSK) last released its earnings data on Wednesday, July 23rd. The company reported $0.65 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.71 by $0.06. Analysts expect that GlaxoSmithKline plc will post $3.24 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Thursday, October 2nd. Investors of record on Friday, August 8th will be given a dividend of $0.6482 per share. This represents a $2.59 dividend on an annualized basis and a yield of 5.44%. The ex-dividend date of this dividend is Wednesday, August 6th.
GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.